Allarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access